Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

Abstract Background and Aim Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements in systemic therapy for HCC are expected to increase the candidates eligible for CS because of the higher...

Full description

Bibliographic Details
Main Authors: Shun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, Yuki Tanaka, Kento Inada, Shun Ishido, Sakura Kirino, Koji Yamashita, Yuka Hayakawa, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Takumi Irie, Shun‐Ichi Ariizumi, Masayuki Kurosaki, Namiki Izumi
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:JGH Open
Subjects:
albumin–bilirubin score
conversion surgery
hepatocellular carcinoma
lenvatinib
sorafenib
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/jgh3.12735

Internet

https://doi.org/10.1002/jgh3.12735

Similar Items